Veterinary Oncology Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (End-use, Animal Type, Cancer Type, Test Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Veterinary Oncology Diagnostics Market size was more than USD 2.5 billion in 2026 and is set to grow at a 7.98% CAGR between 2027 and 2036, exceeding USD 5.39 billion by 2036. The industry revenue for 2027 is assessed at USD 2.67 billion.
Get more details on this report
Request Free Sample ReportVeterinary Oncology Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 56.60% share, driven by advanced veterinary oncology practices, higher diagnostic adoption, and strong pet healthcare spending across specialty clinics and hospitals.
- Asia Pacific is growing at 9.49% CAGR, supported by expanding veterinary infrastructure, increasing awareness of cancer diagnostics, and rising demand for early-stage pet disease detection services.
Segment Momentum
- Veterinary Hospitals & Clinics held a 59.9% share in 2026 because they serve as the primary point of care, integrating cancer evaluation, sample collection, diagnosis, and treatment planning into routine workflows.
- Feline is the fastest-growing animal type as veterinary care increasingly emphasizes comprehensive oncology diagnostics for cats, improving cancer detection and supporting more informed treatment decisions.
Market Expansion Drivers
- Rising prevalence of cancer in companion animals increasing demand for early diagnostic solutions.
- Growing investments in veterinary cancer research accelerating development of advanced diagnostic technologies.
- Increasing pet healthcare awareness expanding adoption of precision oncology testing in veterinary clinics.
Leading Market Participants
- Key companies in the veterinary oncology diagnostics market include IDEXX Laboratories, Inc. (United States), Zoetis Inc. (United States), Mars, Incorporated (Antech Diagnostics) (United States), Neogen Corporation (United States), Thermo Fisher Scientific Inc. (United States), Eurofins Scientific SE (Luxembourg), VolitionRx Limited (United States), Embark Veterinary, Inc. (United States), PetDx, Inc. (United States), Oncotect, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 2.5 billion
- 2027 Estimated Market Size: USD 2.67 billion.
- Projected Market Size: USD 5.39 billion by 2036
- Growth Forecast: 7.98% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Veterinary Hospitals & Clinics (End-use) | Canine (Animal Type) | Skin Cancers (Cancer Type) | Biopsy (Test Type)
- Emerging Opportunity Segment: Reference Laboratories (End-use) | Feline (Animal Type) | Skin Cancers (Cancer Type) | Genome Testing (Test Type)
Market Growth Drivers and Industry Trends
Rising prevalence of cancer in companion animals increasing demand for early diagnostic solutions
The increasing occurrence of cancer among companion animals is creating a larger need for timely and accurate diagnostic assessment, supporting expansion of the veterinary oncology diagnostics market. As pets live longer and receive more comprehensive healthcare, the identification of tumors and other cancer-related abnormalities has become an increasingly important component of veterinary care. Diagnostic solutions that help distinguish suspected cancers, characterize disease, and support clinical evaluation enable veterinarians to make more informed treatment decisions and improve the management of oncology cases.
Growing investments in veterinary cancer research accelerating development of advanced diagnostic technologies
Growing investment in veterinary cancer research is strengthening the veterinary oncology diagnostics market by supporting the development and refinement of diagnostic technologies designed specifically for animal patients. Research activity can improve understanding of tumor biology and encourage the adoption of more sophisticated approaches for identifying and characterizing cancer. Increased funding and scientific attention also support innovation in diagnostic workflows, enabling veterinary professionals to obtain more relevant information for disease assessment and treatment planning.
Increasing pet healthcare awareness expanding adoption of precision oncology testing in veterinary clinics
Greater awareness of pet healthcare is encouraging owners to seek more comprehensive diagnostic and treatment options when cancer is suspected, which is expanding the veterinary oncology diagnostics market. Precision oncology testing can provide veterinarians with more detailed information about the characteristics of a tumor, helping guide clinical decisions and support individualized approaches to cancer management. As pet owners become more attentive to preventive care, diagnostic evaluation, and treatment quality, veterinary clinics are increasingly incorporating specialized oncology testing into their clinical services.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of cancer in companion animals increasing demand for early diagnostic solutions | 2.00% | Moderate | North America, Europe | High | Near Term |
| Growing investments in veterinary cancer research accelerating development of advanced diagnostic technologies | 1.80% | Moderate | North America, Asia Pacific | High | Mid Term |
| Increasing pet healthcare awareness expanding adoption of precision oncology testing in veterinary clinics | 1.50% | Low | Europe, Latin America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The veterinary oncology diagnostics market was led by North America, which captured a 56.60% share in 2026, supported by advanced veterinary healthcare infrastructure, widespread availability of specialized diagnostic services, and strong awareness of companion animal cancer management. Veterinary practices and specialty centers increasingly use sophisticated pathology, imaging, molecular diagnostics, and laboratory testing to support early tumor detection and treatment planning. Rising pet ownership and greater willingness among owners to pursue comprehensive healthcare are strengthening demand for specialized cancer diagnostics. The region's established veterinary research environment and access to advanced clinical expertise further facilitate the adoption of innovative diagnostic approaches.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region, supported by improving veterinary healthcare infrastructure, expanding companion animal populations, and increasing awareness of animal wellness. As veterinary services become more sophisticated, demand is rising for diagnostic tools capable of detecting cancers at earlier stages and supporting more targeted treatment decisions. Urbanization and changing attitudes toward companion animal care are encouraging owners to seek higher-quality medical services, while veterinary hospitals are expanding their diagnostic capabilities. Growing investment in laboratory facilities, specialist training, and advanced veterinary technologies is creating favorable conditions for wider adoption of oncology diagnostics across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Integrated Laboratory ServicesGermany emphasizes integrated laboratory diagnostics that combine pathology, imaging, and biomarker testing for veterinary oncology. German veterinary networks are enhancing diagnostic consistency to improve cancer case management across referral practices.
France 🇫🇷
Clinical Oncology CollaborationFrance encourages closer collaboration between veterinary specialists and diagnostic laboratories to strengthen oncology services. French practices increasingly adopt comprehensive diagnostic workflows that improve cancer classification and treatment planning for companion animals.
Italy 🇮🇹
Pathology Service EnhancementItaly is enhancing veterinary oncology diagnostics through broader adoption of specialized pathology and laboratory services. Italian veterinary clinics are focusing on reliable diagnostic support that enables timely therapeutic decisions and improved patient management.
Japan 🇯🇵
Companion Animal ScreeningJapan is increasing the use of sophisticated oncology diagnostics as companion animal healthcare becomes more preventive. Japanese veterinary clinics are incorporating advanced testing methods that support earlier identification of complex cancer conditions.
South Korea 🇰🇷
Diagnostic Technology AdoptionSouth Korea is expanding access to veterinary oncology diagnostics through investment in laboratory capabilities and advanced testing platforms. South Korean veterinary providers are placing greater emphasis on accurate cancer diagnosis to support individualized treatment strategies.
United States 🇺🇸
Precision Cancer TestingThe U.S. market prioritizes advanced oncology diagnostics that enable earlier cancer detection and personalized treatment planning for companion animals. Veterinary laboratories continue expanding molecular and pathology services to support more informed clinical decisions.
Segment Leadership and Growth Trends
Veterinary Oncology Diagnostics Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Veterinary Hospitals & Clinics (Largest Segment) vs Reference Laboratories (Fastest-Growing Segment)
The veterinary hospitals & clinics segment dominated the veterinary oncology diagnostics market with a 59.9% share in 2026. Its leading position is supported by the role of veterinary care facilities as the primary point of diagnosis, treatment planning, and ongoing monitoring for companion animals with suspected or confirmed cancer. Increasing awareness among pet owners regarding early cancer detection and the growing availability of advanced diagnostic procedures within veterinary practices are further supporting segment demand. Hospitals and clinics also benefit from their ability to integrate diagnostic testing directly into clinical workflows, enabling timely evaluation and treatment decisions.
The reference laboratories segment is expected to be the fastest-growing segment, driven by increasing demand for specialized and high-complexity oncology testing that may not be available within individual veterinary practices. Centralized laboratories provide access to advanced analytical capabilities and specialized expertise, while expanding collaboration with veterinary hospitals and clinics is improving the utilization of outsourced diagnostic services. The growing emphasis on precise cancer characterization and more comprehensive diagnostic evaluation is expected to further strengthen demand for reference laboratory services.
Animal Type Segment Analysis: Canine (Largest Segment) vs Feline (Fastest-Growing Segment)
Holding the largest share of the veterinary oncology diagnostics market, the canine segment accounted for 67.8% in 2026. The segment's dominance is associated with the substantial incidence of cancer among dogs, particularly as companion animals live longer and require more frequent diagnostic assessment for age-related diseases. Greater pet owner awareness, increasing expenditure on veterinary healthcare, and the wider availability of cancer screening and diagnostic procedures for dogs continue to support the segment's position. The strong integration of canine patients into specialized veterinary oncology care also contributes to sustained diagnostic demand.
The feline segment is anticipated to be the fastest-growing segment as awareness of cancer diagnosis and treatment among cat owners and veterinary professionals continues to improve. Historically, cancer symptoms in cats can be difficult to identify at early stages, increasing the importance of diagnostic approaches capable of supporting timely detection and disease characterization. Expanding access to specialized veterinary services and rising investment in companion animal healthcare are expected to accelerate the adoption of oncology diagnostics for feline patients.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Reference Laboratories, Veterinary Hospitals & Clinics | Veterinary Hospitals & Clinics | Reference Laboratories |
| Animal Type | Canine, Feline, Others | Canine | Feline |
| Cancer Type | Lymphoma, Sarcomas, Mammary Gland Tumors, Skin Cancers, Others | Skin Cancers | Skin Cancers |
| Test Type | Blood Tests, Biopsy, Genome Testing, Endoscopy, Urinalysis, Imaging | Biopsy | Genome Testing |
Competitive Landscape and Market Positioning
Key companies in the veterinary oncology diagnostics market:
1. IDEXX Laboratories Inc. (United States)
2. Zoetis Inc. (United States)
3. Mars Incorporated (Antech Diagnostics) (United States)
4. Neogen Corporation (United States)
5. Thermo Fisher Scientific Inc. (United States)
6. Eurofins Scientific SE (Luxembourg)
7. VolitionRx Limited (United States)
8. Embark Veterinary Inc. (United States)
9. PetDx Inc. (United States)
10. Oncotect Inc. (United States)
The veterinary oncology diagnostics market is witnessing rising innovation as demand increases for early cancer detection and precision veterinary care solutions. Diagnostic developers are expanding biomarker research, molecular testing capabilities, and AI-assisted imaging technologies to improve clinical outcomes for companion animals. Partnerships with veterinary research centers are also supporting the introduction of more advanced and accessible oncology diagnostic services.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| IDEXX Laboratories Inc. (United States) | |||||||
| Zoetis Inc. (United States) | |||||||
| Mars Incorporated (Antech Diagnostics) (United States) | |||||||
| Neogen Corporation (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Eurofins Scientific SE (Luxembourg) | |||||||
| VolitionRx Limited (United States) | |||||||
| Embark Veterinary Inc. (United States) | |||||||
| PetDx Inc. (United States) | |||||||
| Oncotect Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Torigen Pharmaceuticals | Dec-24 | Torigen Pharmaceuticals launched the Torigen Specialty Pathology service, offering expert-reviewed cancer diagnostics with a 3-to-5 day turnaround time. The service provides actionable reporting and is designed to integrate directly with the company’s existing personalized cancer immunotherapy platforms, streamlining the diagnostic-to-treatment workflow for veterinary practitioners managing complex pet oncology cases. |
| Cancan Diagnostics | Sep-24 | Cancan Diagnostics entered a strategic distribution partnership with Vet Planet Ltd. to commercialize the K9-LiquiDX diagnostic tool. The rollout targets markets across Mainland Europe, APAC, the Middle East, and South America, focusing on advanced early relapse detection and longitudinal monitoring of canine cancer to provide veterinarians with actionable diagnostic capabilities for improved treatment tracking. |
| Antech | Apr-24 | Antech launched the Nu.Q Canine Cancer Test in Europe, providing a rapid in-clinic diagnostic tool for detecting common cancers such as lymphoma and hemangiosarcoma. By delivering results in 5–10 minutes, the test enables veterinary professionals to expedite clinical decision-making and enhance the management of oncology cases in high-risk canine patients. |
| VolitionRx | Mar-24 | VolitionRx partnered with Fujifilm Vet Systems to launch the Nu.Q Vet Cancer Test in Japan. This collaboration integrates the test into Fujifilm’s extensive reference laboratory network, significantly broadening access to early cancer screening services for dogs and improving the standard of patient care for veterinary clinics across the Japanese market. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Veterinary Oncology Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood & Serum, Tissue & Biopsy, Urine, Cytology Samples, Other Biological Samples |
| Disease Stage | Suspected Disease, Newly Diagnosed Disease, Active Disease Monitoring, Post-Treatment Surveillance |
| Ownership Type | Privately Owned Veterinary Practices, Corporate Veterinary Groups, Nonprofit & Public Veterinary Facilities, Academic Veterinary Institutions |
Veterinary Oncology Diagnostics Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Veterinary Cancer Care Pathway Analysis |
|
| Companion Animal Oncology Growth Assessment |
|
| Precision Veterinary Oncology Outlook |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the veterinary oncology diagnostics market generate?
What is the forecasted size of the veterinary oncology diagnostics industry?
How is rising cancer prevalence in companion animals influencing demand for oncology diagnostics?
How are research investments shaping adoption of advanced veterinary oncology diagnostic tools?
Why are Veterinary Hospitals & Clinics the largest end-use segment in the veterinary oncology diagnostics market?
Which animal type is growing fastest in the veterinary oncology diagnostics market?
Why does North America lead the veterinary oncology diagnostics market?
What is driving Asia Pacific growth in veterinary oncology diagnostics?
What are the prominent companies operating in the veterinary oncology diagnostics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization